

## Inhibition of Na<sup>+</sup> Channel or Na<sup>+</sup>/H<sup>+</sup> Exchanger Attenuates the Hydrogen Peroxide-induced Derangements in Isolated Perfused Rat Heart

AKIYOSHI HARA, JOHJI ARAKAWA\*, CHUN-YANG XIAO, HIROKO HASHIZUME, FUMITAKA USHIKUBI AND YASUSHI ABIKO

*Department of Pharmacology, Asahikawa Medical College, Asahikawa and*

*\*Department of Anesthesiology, Sapporo Medical University School of Medicine, Sapporo, Japan*

---

### Abstract

The effect of tetrodotoxin, a specific inhibitor of the Na<sup>+</sup> channel, and 5-(*N,N*-dimethyl)-amiloride, a specific inhibitor of the Na<sup>+</sup>/H<sup>+</sup> exchanger, on the mechanical and metabolic derangements induced by hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) was studied in the isolated perfused rat heart. The isolated rat heart was perfused aerobically at a constant flow rate and driven electrically.

H<sub>2</sub>O<sub>2</sub> (600 μM) decreased the left ventricular developed pressure and increased the left ventricular end-diastolic pressure (i.e. mechanical dysfunction), decreased the tissue levels of adenosine triphosphate and adenosine diphosphate (i.e. metabolic derangement), and increased the tissue level of malondialdehyde (i.e. lipid peroxidation). These mechanical and metabolic derangements induced by H<sub>2</sub>O<sub>2</sub> were significantly attenuated by tetrodotoxin (3 μM) or 5-(*N,N*-dimethyl)-amiloride (15 μM). Neither tetrodotoxin nor 5-(*N,N*-dimethyl)-amiloride modified the tissue malondialdehyde level, which was increased by H<sub>2</sub>O<sub>2</sub>. In the normal (H<sub>2</sub>O<sub>2</sub>-untreated) heart, neither tetrodotoxin nor 5-(*N,N*-dimethyl)-amiloride affected the mechanical function and energy metabolism.

These results suggested that inhibition of the Na<sup>+</sup> channel or Na<sup>+</sup>/H<sup>+</sup> exchanger was effective in attenuating the H<sub>2</sub>O<sub>2</sub>-induced mechanical dysfunction and metabolic derangements in the isolated perfused rat heart.

---

It has been generally accepted that the primary mechanism of action of anti-anginal drugs is improvement of the myocardial oxygen balance between supply and demand by either an increase in coronary flow or a decrease in cardiac mechanical function, or both. Therefore, nitrates, β-adrenoceptor antagonists and Ca<sup>2+</sup>-channel inhibitors have been used widely for treatment of patients with ischaemic heart disease. The beneficial action of inhibitors of the Na<sup>+</sup> channel, such as tetrodotoxin (Duff et al 1988) and lidocaine (Okamura et al 1982; Takeo et al 1988; Nakamura et al 1989), and that of inhibitors of the Na<sup>+</sup>/H<sup>+</sup> exchanger, such as amiloride (Nasa et al 1997) and its derivative (Dennis et al 1990; Meng & Pierce 1990; Maddaford & Pierce 1997), on the ischaemia-reperfused heart have been demonstrated in animal

models. Interestingly, inhibitors of the Na<sup>+</sup> channel (Okamura et al 1982; Duff et al 1988; Takeo et al 1988) and those of the Na<sup>+</sup>/H<sup>+</sup> exchanger (Dennis et al 1990; Meng & Pierce 1990; Nasa et al 1997) are effective in attenuating ischaemia-reperfusion damage, even when they do not exert a significant effect on haemodynamics. Therefore, the protective action of these inhibitors may not be due to improvement of the myocardial oxygen balance induced by haemodynamic effects, but possibly due to inhibition of intracellular Na<sup>+</sup> accumulation during ischaemia (Pike et al 1993; Van Emous et al 1997). Nevertheless, the detailed mechanism of the protective action of inhibitors of the Na<sup>+</sup> channel and Na<sup>+</sup>/H<sup>+</sup> exchanger on the ischaemia-reperfusion damage remains unclear.

During ischaemia and reperfusion, reactive oxygen species, such as superoxide anion, hydroxyl radical, hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) and singlet oxygen, are generated intra- and extracellularly in

the myocardium and endothelium (Hess & Manson 1984; Lucchesi 1990; Loesser et al 1991). These reactive oxygen species cause lipid peroxidation of the cell membrane and myocardial derangements including mechanical dysfunction and energy deficiency (Hess & Manson 1984; Nakaya et al 1987; Loesser et al 1991). Therefore, reactive oxygen species are an important factor inducing myocardial damage during ischaemia and reperfusion. We (Hara et al 1993; Hara & Abiko 1996) have demonstrated that treatment of the isolated perfused rat heart with  $H_2O_2$  inflicts severe damage on the mechanical function and energy metabolism, including lipid peroxidation. According to the results of a study using nuclear magnetic resonance (Yanagida et al 1995),  $H_2O_2$  increases intracellular  $Na^+$  concentration in the myocardium. Kim & Akera (1987) reported that the  $H_2O_2$ -induced increase in intracellular  $Na^+$  concentration may be due, in part, to the inhibition of the sarcolemmal  $Na^+, K^+$ ATPase. An increase in intracellular  $Na^+$  concentration could cause intracellular  $Ca^{2+}$  overload through the  $Na^+/Ca^{2+}$  exchanger, and hence myocardial derangements (Goldhaber 1996). Therefore, inhibitors of the  $Na^+$  channel and  $Na^+/H^+$  exchanger may be effective in attenuating  $H_2O_2$ -induced myocardial derangements via inhibition of  $Na^+$  entry into the myocardial cell.

There is no report, however, on the action of  $Na^+$ -channel inhibitors  $Na^+/H^+$ -exchange inhibitors against the  $H_2O_2$ -induced myocardial damage. In addition, there is no report on whether the cardioprotective effects of these drugs are based on inhibition of lipid peroxidation in the myocardium. This study examined whether a  $Na^+$ -channel inhibitor or a  $Na^+/H^+$ -exchange inhibitor protects the  $H_2O_2$ -induced derangements in both mechanical function and energy metabolism and attenuates the  $H_2O_2$ -induced lipid peroxidation. We chose tetrodotoxin and 5-(*N,N*-dimethyl)-amiloride as a specific  $Na^+$ -channel inhibitor and a specific  $Na^+/H^+$ -exchange inhibitor, respectively, because tetrodotoxin and 5-(*N,N*-dimethyl)-amiloride may attenuate the  $H_2O_2$ -induced increase in intracellular concentration of  $Na^+$  by different mechanisms.

## Materials and Methods

### *Heart perfusion*

The Asahikawa Medical College Committee on Animal Research approved the protocol of animal experiments in this study. Male Sprague–Dawley rats (9–10-weeks old; Sankyo Labo Service Corporation, Sapporo) were anaesthetized with sodium

pentobarbital (50 mg kg<sup>-1</sup>, i.p.) 20 min after an injection with heparin (1000 units kg<sup>-1</sup>, i.p.). After thoracotomy, the hearts were rapidly removed, and then retrograde perfusion was started using a cannula inserted into the aorta according to the Langendorff technique. The perfusion buffer was a Krebs–Henseleit bicarbonate (KHB) buffer containing (mM) NaCl 118, KCl 4.7,  $KH_2PO_4$  1.2,  $MgSO_4$  1.2,  $CaCl_2$  2.5,  $NaHCO_3$  25 and glucose 11, equilibrated with a gas mixture of 95%  $O_2$  and 5%  $CO_2$  and maintained at 37°C. The oxygen tension of the buffer measured by a blood gas analyser (Model 813, Instrumentation Laboratory, Lexington, MA) was about 550 mmHg. The hearts were initially perfused at a constant perfusion pressure of 80 cm  $H_2O$ . About 10 min after constant pressure perfusion, perfusion was switched to the constant flow perfusion (10 mL min<sup>-1</sup>) using a microtube pump (Eyela MP-A, Tokyo-Rikakikai Instruments, Tokyo, Japan), and this flow rate was maintained throughout the experiment. The heart rate of spontaneously beating hearts was about 270 beats min<sup>-1</sup>, but it was kept constant by pacing the heart at 300 beats min<sup>-1</sup> with an electronic stimulator (3F46, San-Ei Instruments, Tokyo, Japan) during the course of the study. Rectangular pulses having 2-ms duration with a voltage of 6 V (about 3-times the threshold voltage) were applied to the left ventricle for this pacing.

As indices of mechanical function, left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), and left ventricular developed pressure (LVDP) were employed. The values of LVSP and LVEDP were determined from the left ventricular pressure (LVP) curves recorded continuously during the course of the study, and the LVDP value was calculated as LVSP minus LVEDP. For measurement of LVP, a saline-filled polyethylene cannula, connected to a pressure transducer, was inserted into the left ventricular cavity via the left atrium. Another pressure transducer was connected to the aortic cannula for the recording of coronary perfusion pressure. Before the start of each experiment, the heart was allowed to stabilize for 20 min under the conditions of constant flow perfusion.

### *Experimental protocol*

The heart was perfused with KHB buffer at a constant flow throughout the whole course of the experiments (stabilization period for 20 min and observation period for 38 min). During the observation period,  $H_2O_2$  and/or a drug (tetrodotoxin or 5-(*N,N*-dimethyl)-amiloride) were infused into the aortic cannula in which KHB buffer flowed. The

effect of tetrodotoxin or 5-(*N,N*-dimethyl)-amiloride on the mechanical function and energy metabolism in both H<sub>2</sub>O<sub>2</sub>-treated and H<sub>2</sub>O<sub>2</sub>-untreated (normal) hearts was examined. In the H<sub>2</sub>O<sub>2</sub>-treated heart experiments, the hearts were divided into five groups; vehicle, tetrodotoxin 1  $\mu$ M, tetrodotoxin 3  $\mu$ M, 5-(*N,N*-dimethyl)-amiloride 5  $\mu$ M, and 5-(*N,N*-dimethyl)-amiloride 15  $\mu$ M groups. In these groups, tetrodotoxin, 5-(*N,N*-dimethyl)-amiloride or vehicle (KHB buffer) was infused into the aortic cannula for 38 min at a constant flow rate of 0.1 mL min<sup>-1</sup>. H<sub>2</sub>O<sub>2</sub> was infused into the aortic cannula at the constant flow rate of 0.1 mL min<sup>-1</sup> for 3 min from 5 min after the start of infusion of tetrodotoxin, 5-(*N,N*-dimethyl)-amiloride or vehicle. In the normal heart experiments, the hearts were divided into five groups; vehicle, tetrodotoxin 1  $\mu$ M, tetrodotoxin 3  $\mu$ M, 5-(*N,N*-dimethyl)-amiloride 5  $\mu$ M, and 5-(*N,N*-dimethyl)-amiloride 15  $\mu$ M groups. The experimental conditions and protocol in the normal heart experiments were essentially the same as those in the H<sub>2</sub>O<sub>2</sub>-treated heart experiments, except for an infusion of saline solution instead of H<sub>2</sub>O<sub>2</sub> solution. In each group, LVSP, LVEDP and coronary perfusion pressure were continuously recorded over a 38-min observation period. To measure the tissue levels of high-energy phosphates, the heart was frozen at the end of the observation period (38 min after the start of infusion of tetrodotoxin, 5-(*N,N*-dimethyl)-amiloride or vehicle) with freezing clamps previously chilled in liquid nitrogen.

Some hearts in the vehicle group in the normal heart experiments and those in the vehicle, tetrodotoxin 3  $\mu$ M and 5-(*N,N*-dimethyl)-amiloride 15  $\mu$ M groups in the H<sub>2</sub>O<sub>2</sub> heart experiments were frozen 10 min after the end of H<sub>2</sub>O<sub>2</sub> infusion (18 min after the start of infusion of tetrodotoxin, 5-(*N,N*-dimethyl)-amiloride or vehicle) for measurement of the tissue level of malondialdehyde.

#### *Biochemical analysis*

The myocardial samples were stored in liquid nitrogen (-196°C) until the biochemical analysis was performed. Each frozen sample was pulverized in a mortar cooled with liquid nitrogen. Part of the pulverized tissue powder was weighed and put into an oven overnight to enable measurement of the tissue water content and dry weight of the tissue. The remainder of the tissue powder was used for determination of tissue levels of adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), creatine phosphate and malondialdehyde. ATP, ADP, AMP and creatine phosphate were measured according to

standard enzymatic procedures (Bergmeyer 1974). Malondialdehyde, a product of lipid peroxidation, was measured using HPLC instead of using thio-barbituric acid, because using the latter method may measure not only malondialdehyde but also other substances (Ceconi et al 1991). The HPLC procedure was performed according to the method of Koller & Bergmann (1989). Before measurement of the tissue malondialdehyde level, we confirmed that tetrodotoxin or 5-(*N,N*-dimethyl)-amiloride did not interfere with measurement of malondialdehyde. The procedure for measurements of energy metabolites and malondialdehyde was as described previously (Hara et al 1993; Hara & Abiko 1996).

#### *Drugs*

Tetrodotoxin (Sankyo Co., Ltd, Tokyo, Japan) and 5-(*N,N*-dimethyl)-amiloride (Research Biochemicals, Natick, MA) were dissolved in KHB buffer solution. H<sub>2</sub>O<sub>2</sub> (Nacalai Tesque Ltd, Kyoto, Japan) was diluted with saline solution. Tetrodotoxin, 5-(*N,N*-dimethyl)-amiloride or vehicle (KHB buffer) solution was infused at a flow rate of 0.1 mL min<sup>-1</sup> using an infusion pump into the inflow tube connected to the side arm of the aortic cannula. 5-(*N,N*-Dimethyl)-amiloride is unstable in white light so the drug solution was prepared under the light of a sodium lamp. In addition, the inflow tube and a syringe for drug infusion were shielded from light by an aluminum cover throughout the experiment. H<sub>2</sub>O<sub>2</sub> or saline solution was also infused to the inflow tube at a flow rate of 0.1 mL min<sup>-1</sup> using another infusion pump. The final concentration of tetrodotoxin in the perfusate (KHB buffer perfused at a flow rate of 10 mL min<sup>-1</sup> plus tetrodotoxin solution infused at a flow rate of 0.1 mL min<sup>-1</sup>) was set to 1 or 3  $\mu$ M. Nevertheless, the concentration of tetrodotoxin changed from 1 to 0.99  $\mu$ M or 3 to 2.97  $\mu$ M when H<sub>2</sub>O<sub>2</sub> was added to the perfusate, because total flow rate of perfusate increased from 10.1 to 10.2 mL min<sup>-1</sup> during the H<sub>2</sub>O<sub>2</sub> infusion. 5-(*N,N*-Dimethyl)-amiloride was also infused into the aortic cannula at a flow rate of 0.1 mL min<sup>-1</sup> so that the final concentration of 5-(*N,N*-dimethyl)-amiloride in the perfusate was 5 or 15  $\mu$ M, although the concentration changed from 5 to 4.95  $\mu$ M or 15 to 14.85  $\mu$ M during the infusion of H<sub>2</sub>O<sub>2</sub>. These small changes in the concentration of tetrodotoxin or 5-(*N,N*-dimethyl)-amiloride were about 1% and did not affect LVP. The final concentration of H<sub>2</sub>O<sub>2</sub> in the perfusate including infusion solution was 600  $\mu$ M. The reagents and enzymes used for biochemical analysis were purchased from Sigma Chemical Company (St Louis,

MO) or Aldrich Chemical Company (Milwaukee, WI).

### Statistical analysis

All values are expressed as mean  $\pm$  s.e.m. When data of mechanical function and coronary perfusion pressure were compared between vehicle-treated and drug-treated groups, statistical analysis was performed with a two-way repeated measures analysis of variance followed by Dunnett's test for multiple comparison (Figures 1, 2, 3 and 4). When metabolic data in the vehicle group were compared between  $H_2O_2$ -treated and normal ( $H_2O_2$ -untreated) groups, unpaired Student's *t*-test was employed (Figure 5). When other biochemical data were compared between vehicle-treated and drug-treated groups, statistical analysis was performed with a one-way analysis of variance followed by Dunnett's test for multiple comparison (Figure 5 and Table 1). A difference was considered statistically significant at  $P < 0.05$ .

## Results

### Effects of tetrodotoxin and 5-(*N,N*-dimethyl)-amiloride on $H_2O_2$ -induced changes in mechanical function and coronary resistance

In the normal ( $H_2O_2$ -untreated) heart, tetrodotoxin (1 and 3  $\mu M$ ) and 5-(*N,N*-dimethyl)-amiloride (5 and 15  $\mu M$ ) did not have any effect on the LVSP ( $P > 0.05$ ), LVEDP ( $P > 0.05$ ) or coronary perfusion pressure ( $P > 0.05$ ) during the whole course of the study (data not shown). Figures 1 and 2 show the effects of tetrodotoxin and 5-(*N,N*-dimethyl)-amiloride, respectively, on the  $H_2O_2$ -induced changes in LVSP and LVEDP. Before starting the  $H_2O_2$  infusion, there was no significant difference in the values of LVSP and LVEDP between the vehicle and tetrodotoxin groups and between the vehicle and 5-(*N,N*-dimethyl)-amiloride groups. In the vehicle group,  $H_2O_2$  decreased LVSP temporarily but markedly ( $P < 0.001$ ). The LVSP, which had been decreased by  $H_2O_2$ , increased after the end of  $H_2O_2$  infusion and returned to the initial level.  $H_2O_2$  also increased LVEDP markedly ( $P < 0.001$ ), and the increase in LVEDP was accompanied by an increase in LVSP. The increase in LVEDP induced by  $H_2O_2$  was prevented almost completely by tetrodotoxin (3  $\mu M$ ) or 5-(*N,N*-dimethyl)-amiloride (15  $\mu M$ ) ( $P < 0.05$  compared with the vehicle group). A low concentration of tetrodotoxin (1  $\mu M$ ) also attenuated the  $H_2O_2$ -induced increase in LVEDP ( $P < 0.05$  compared




Figure 1. Effect of tetrodotoxin (1 and 3  $\mu M$ ) on the hydrogen peroxide ( $H_2O_2$ )-induced changes in left ventricular pressure (LVP). The changes in left ventricular systolic pressure ( $\circ$ ) and left ventricular end-diastolic pressure ( $\bullet$ ) in the vehicle, tetrodotoxin 1  $\mu M$  and 3  $\mu M$  groups are recorded. Each value represents mean  $\pm$  s.e.m. of 7–19 hearts. \* $P < 0.05$  when compared with the vehicle group.

with the vehicle group). However, a low concentration of 5-(*N,N*-dimethyl)-amiloride (5  $\mu M$ ) was actually ineffective in attenuating the  $H_2O_2$ -induced increase in LVEDP.

Figure 3 shows the effects of tetrodotoxin and 5-(*N,N*-dimethyl)-amiloride on the  $H_2O_2$ -induced changes in LVDP. Before starting the  $H_2O_2$  infusion, there was no significant difference in the LVDP value between the vehicle and tetrodotoxin or 5-(*N,N*-dimethyl)-amiloride groups. In the vehicle group,  $H_2O_2$  decreased LVDP markedly ( $P < 0.001$ ). The decrease in LVDP induced by  $H_2O_2$  was attenuated by tetrodotoxin (3  $\mu M$ ) or 5-(*N,N*-dimethyl)-amiloride (15  $\mu M$ ). Nevertheless, a low concentration of tetrodotoxin (1  $\mu M$ ) or 5-(*N,N*-dimethyl)-amiloride (5  $\mu M$ ) was actually ineffective in attenuating the  $H_2O_2$ -induced decrease in LVDP. These results indicated that tetrodotoxin and 5-(*N,N*-dimethyl)-amiloride attenuated the mechanical dysfunction induced by  $H_2O_2$ .




Figure 2. Effect of 5-(*N,N*-dimethyl)-amiloride (5 and 15  $\mu\text{M}$ ) on the H<sub>2</sub>O<sub>2</sub>-induced changes in left ventricular pressure (LVP). The changes of left ventricular systolic pressure (LVP) and left ventricular end-diastolic pressure (LVEDP) in the vehicle, 5-(*N,N*-dimethyl)-amiloride 5  $\mu\text{M}$  and 15  $\mu\text{M}$  groups are recorded. Hearts in the vehicle group are those in Figure 1. Each value represents mean  $\pm$  s.e.m. of 9–19 hearts. \* $P < 0.05$  when compared with the vehicle group.

Figure 4 shows the effects of tetrodotoxin and 5-(*N,N*-dimethyl)-amiloride on the H<sub>2</sub>O<sub>2</sub>-induced changes in coronary perfusion pressure. Before starting the H<sub>2</sub>O<sub>2</sub> infusion, there was no significant difference in the coronary perfusion pressure value between the vehicle and tetrodotoxin or 5-(*N,N*-dimethyl)-amiloride groups. In the vehicle group, H<sub>2</sub>O<sub>2</sub> induced a transient and slight decrease in coronary perfusion pressure followed by a continuous and marked increase ( $P < 0.001$ ). The increase in coronary perfusion pressure induced by H<sub>2</sub>O<sub>2</sub> was attenuated by tetrodotoxin (3  $\mu\text{M}$ ) or 5-(*N,N*-dimethyl)-amiloride (15  $\mu\text{M}$ ) ( $P < 0.05$  compared with the vehicle group). Nevertheless, a low concentration of tetrodotoxin (1  $\mu\text{M}$ ) or 5-(*N,N*-dimethyl)-amiloride (5  $\mu\text{M}$ ) did not attenuate the H<sub>2</sub>O<sub>2</sub>-induced increase in coronary perfusion pressure, except for 10.5 to 18 min after starting the tetrodotoxin (1  $\mu\text{M}$ ) infusion. These results indi-




Figure 3. Effect of tetrodotoxin or 5-(*N,N*-dimethyl)-amiloride on the H<sub>2</sub>O<sub>2</sub>-induced changes in left ventricular developed pressure (LVDP). a. The changes in LVDP in the vehicle ( $\circ$ ), tetrodotoxin 1  $\mu\text{M}$  ( $\bullet$ ) and tetrodotoxin 3  $\mu\text{M}$  ( $\blacktriangle$ ) groups. b. The changes of LVDP in the vehicle ( $\circ$ ), 5-(*N,N*-dimethyl)-amiloride 5  $\mu\text{M}$  ( $\bullet$ ) and 5-(*N,N*-dimethyl)-amiloride 15  $\mu\text{M}$  ( $\blacktriangle$ ) groups. Values were calculated from the values of left ventricular systolic pressure and left ventricular end-diastolic pressure in Figures 1 and 2. Hearts in the vehicle group are the same hearts for a and b. Each value represents mean  $\pm$  s.e.m. of 7–19 hearts. \* $P < 0.05$  when compared with the vehicle group.

cated that tetrodotoxin and 5-(*N,N*-dimethyl)-amiloride attenuated the increase in coronary perfusion pressure, and hence coronary resistance (because the perfusion flow was fixed) induced by H<sub>2</sub>O<sub>2</sub>.

#### Effects of tetrodotoxin and 5-(*N,N*-dimethyl)-amiloride on H<sub>2</sub>O<sub>2</sub>-induced changes in energy metabolism

Figure 5 shows the tissue levels of ATP, ADP, AMP and creatine phosphate at the end of experiment in the normal (H<sub>2</sub>O<sub>2</sub>-untreated) and H<sub>2</sub>O<sub>2</sub>-treated hearts. In the normal (H<sub>2</sub>O<sub>2</sub>-untreated) heart, the tissue levels of ATP, ADP, AMP and creatine phosphate were similar between the vehicle and each of the tetrodotoxin or 5-(*N,N*-dimethyl)-amiloride groups. In the H<sub>2</sub>O<sub>2</sub>-treated heart, H<sub>2</sub>O<sub>2</sub> decreased the tissue levels of ATP, ADP and creatine phosphate ( $P < 0.05$  between the normal and H<sub>2</sub>O<sub>2</sub>-treated groups), and increased the tissue level of AMP ( $P < 0.05$  between the normal and




Figure 4. Effect of tetrodotoxin or 5-(*N,N*-dimethyl)-amiloride on the  $H_2O_2$ -induced changes in coronary perfusion pressure. a. The changes in coronary perfusion pressure in the vehicle (○), tetrodotoxin 1  $\mu M$  (●) and tetrodotoxin 3  $\mu M$  (▲) groups. b. The changes of coronary perfusion pressure in the vehicle (○), 5-(*N,N*-dimethyl)-amiloride 5  $\mu M$  (●) and 5-(*N,N*-dimethyl)-amiloride 15  $\mu M$  (▲) groups. Hearts were those in Figures 1 and 2. Hearts in the vehicle group are the same hearts for a and b. Each value represents mean  $\pm$  s.e.m. of 7–19 hearts. \* $P < 0.05$  when compared with the vehicle group.

$H_2O_2$ -treated groups). These changes of the tissue levels of energy metabolites induced by  $H_2O_2$ , however, were attenuated significantly by tetrodotoxin (3  $\mu M$ ) or 5-(*N,N*-dimethyl)-amiloride (15  $\mu M$ ) ( $P < 0.05$  compared with the vehicle group). Nevertheless, a low concentration of tetrodotoxin (1  $\mu M$ ) or 5-(*N,N*-dimethyl)-amiloride (5  $\mu M$ ) failed to attenuate the  $H_2O_2$ -induced decrease in the tissue levels of ATP, ADP and creatine phosphate, although they attenuated the  $H_2O_2$ -induced increase in the tissue level of AMP. These results indicated that tetrodotoxin and 5-(*N,N*-dimethyl)-amiloride attenuated the metabolic derangements induced by  $H_2O_2$ .

#### Effects of tetrodotoxin and 5-(*N,N*-dimethyl)-amiloride on $H_2O_2$ -induced lipid peroxidation

There is a possibility that the beneficial effects of tetrodotoxin and 5-(*N,N*-dimethyl)-amiloride on the  $H_2O_2$ -induced derangements relate to the reduction of lipid peroxidation that could be increased by  $H_2O_2$ . To examine this possibility, the tissue level

of malondialdehyde was measured in the normal ( $H_2O_2$ -untreated), vehicle, tetrodotoxin 3  $\mu M$ , and 5-(*N,N*-dimethyl)-amiloride 15  $\mu M$  groups (Table 1). Previously, we reported (Hara et al 1993) that the tissue level of malondialdehyde, which had been increased by  $H_2O_2$ , decreased by prolongation of the period of heart perfusion after the end of  $H_2O_2$  infusion, because malondialdehyde can be washed out into myocardial interstitial effluent (Koster et al 1985). Therefore, we measured the tissue malondialdehyde level shortly after the end of  $H_2O_2$  infusion; 10 min was used as it corresponds to the time when  $H_2O_2$  produced a marked increase in LVEDP and when the increase in LVEDP was inhibited by tetrodotoxin (3  $\mu M$ ) and 5-(*N,N*-dimethyl)-amiloride (15  $\mu M$ ). In the vehicle group,  $H_2O_2$  increased the tissue malondialdehyde level by about three times the value in the normal group ( $P < 0.05$ ). There was, however, no statistical difference in the tissue level of malondialdehyde between vehicle and tetrodotoxin 3  $\mu M$  or between vehicle and 5-(*N,N*-dimethyl)-amiloride 15  $\mu M$  groups. These results indicated that tetrodotoxin or 5-(*N,N*-dimethyl)-amiloride did not reduce the lipid peroxidation induced by  $H_2O_2$ .

## Discussion

In this study, we used  $H_2O_2$  as a reactive oxygen species for three reasons. Firstly,  $H_2O_2$  and its metabolite, hydroxyl radical, are considered important in the pathogenesis of myocardial damage induced by ischaemia–reperfusion (Brown et al 1988; Loesser et al 1991). Secondly,  $H_2O_2$  penetrates the cell membrane and reaches the intracellular site (Fisher 1988), and therefore it may cause severe damage to the cell. Thirdly, 600  $\mu M$   $H_2O_2$  can inflict damage to the heart to a degree

Table 1. Effect of tetrodotoxin and 5-(*N,N*-dimethyl)-amiloride on hydrogen peroxide ( $H_2O_2$ )-induced changes of the tissue level of malondialdehyde.

Group	n	Tissue malondialdehyde level (nmol g <sup>-1</sup> dry weight)
Normal ( $H_2O_2$ -untreated)	8	9.9 $\pm$ 1.4*
Vehicle	12	29.7 $\pm$ 2.7
Tetrodotoxin (3 $\mu M$ )	7	32.7 $\pm$ 3.2
5-( <i>N,N</i> -Dimethyl)-amiloride (15 $\mu M$ )	8	36.5 $\pm$ 3.8

Each value represents the mean  $\pm$  s.e.m. n represents the number of hearts. The tissue level of malondialdehyde was measured 10 min after the end of  $H_2O_2$  infusion. The final concentrations of tetrodotoxin, 5-(*N,N*-dimethyl)-amiloride and  $H_2O_2$  in the perfusate were 3, 15 and 600  $\mu M$ , respectively. \* $P < 0.05$  when compared with vehicle group.




Figure 5. Effect of tetrodotoxin (1 and 3 μM) or 5-(*N,N*-dimethyl)-amiloride (5 and 15 μM) on the H<sub>2</sub>O<sub>2</sub>-induced changes in the tissue levels of high-energy phosphates. The tissue levels of adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP) and creatine phosphate at the end of experiment (38 min after the start of tetrodotoxin, 5-(*N,N*-dimethyl)-amiloride or vehicle infusion) were measured in the normal (H<sub>2</sub>O<sub>2</sub>-untreated) and H<sub>2</sub>O<sub>2</sub>-treated hearts. Hearts in the H<sub>2</sub>O<sub>2</sub>-treated groups are those in Figures 1 and 2. Each value represents a mean ± s.e.m. of 5–7 hearts (the normal groups) and 7–19 hearts (the H<sub>2</sub>O<sub>2</sub>-treated groups). \**P* < 0.05 when compared with the corresponding normal group. †*P* < 0.05 when compared with the vehicle group in the H<sub>2</sub>O<sub>2</sub>-treated heart.

similar to that induced by ischaemia–reperfusion in terms of accumulation of lipid peroxides (Hara et al 1993). In this study, H<sub>2</sub>O<sub>2</sub> produced mechanical dysfunction (as evidenced by an increase in LVEDP and a decrease in LVDP), an increase in coronary resistance (as evidenced by an increase in coronary perfusion pressure), and metabolic changes (as evidenced by a decrease in the tissue levels of ATP and ADP and an increase in the tissue level of AMP). These alterations induced by H<sub>2</sub>O<sub>2</sub> were significantly attenuated by tetrodotoxin (3 μM) or 5-(*N,N*-dimethyl)-amiloride (15 μM), suggesting that both drugs have a beneficial effect against the H<sub>2</sub>O<sub>2</sub>-induced mechanical and metabolic derangements in the heart. The beneficial effect of tetrodotoxin and 5-(*N,N*-dimethyl)-amiloride was observed on the H<sub>2</sub>O<sub>2</sub>-induced mechanical dys-

function in terms of recovery of LVEDP and LVDP but not LVSP, suggesting that both drugs improved the ability of the heart to relax. Cardiac contraction and relaxation are under control of the sarcoplasmic reticulum; contraction from release of Ca<sup>2+</sup> from the sarcoplasmic reticulum and relaxation from its uptake of Ca<sup>2+</sup>. H<sub>2</sub>O<sub>2</sub> inhibits the Ca<sup>2+</sup> uptake (Rowe et al 1983) and so it impairs sarcoplasmic reticulum function and hence causes mechanical dysfunction of the heart. The action of tetrodotoxin and 5-(*N,N*-dimethyl)-amiloride on cardiac contraction and relaxation may be due to a reduction of Ca<sup>2+</sup> entry into myocytes, which is a conceivable consequence of inhibition of Na<sup>+</sup> entry into myocytes.

The concentrations of tetrodotoxin (1 and 3 μM) and 5-(*N,N*-dimethyl)-amiloride (5 and 15 μM) used

did not modify mechanical function in the normal ( $\text{H}_2\text{O}_2$ -untreated) heart. These agents did not change coronary flow, because the hearts were perfused at a constant flow rate. It is unlikely, therefore, that the protective effects of tetrodotoxin and 5-(*N,N*-dimethyl)-amiloride on the  $\text{H}_2\text{O}_2$ -induced myocardial derangements were due to preservation of energy caused by favourable action of these drugs on haemodynamics i.e. an energy-sparing effect. In fact, neither tetrodotoxin nor 5-(*N,N*-dimethyl)-amiloride had any effect on the tissue levels of high-energy phosphates in the normal,  $\text{H}_2\text{O}_2$ -untreated, heart.

Some radical scavengers or antioxidants have been demonstrated to protect the myocardium against oxidative stress (Nakaya et al 1987; Koller & Bergmann 1989). We have reported that in the isolated perfused rat heart, catalase, an  $\text{H}_2\text{O}_2$  scavenger (Hara et al 1993), or propofol, an intravenous anaesthetic with an antioxidant action (Kokita & Hara 1996), attenuates  $\text{H}_2\text{O}_2$ -induced mechanical and metabolic derangements and lipid peroxidation. In this study, however, neither tetrodotoxin nor 5-(*N,N*-dimethyl)-amiloride affected the  $\text{H}_2\text{O}_2$ -induced lipid peroxidation, suggesting that the protective effect of tetrodotoxin and 5-(*N,N*-dimethyl)-amiloride was not due to a radical scavenging or an antioxidant effect.

Tetrodotoxin selectively inhibits the  $\text{Na}^+$  channel without affecting the  $\text{Ca}^{2+}$  channel (Tytgat et al 1990) and  $\text{Na}^+/\text{Ca}^{2+}$  exchanger (Requena et al 1985). According to binding studies (Catterall & Coppersmith 1981; Rogart 1987), the concentrations of tetrodotoxin used in this study, which attenuated the  $\text{H}_2\text{O}_2$ -induced derangements (1 and 3  $\mu\text{M}$ ), were capable of inhibiting the  $\text{Na}^+$  channel in the rat heart (dissociation constant = 0.3 to 1  $\mu\text{M}$ ). In addition, we have found that lidocaine (Hara et al 1993) and dilazep (Hara & Abiko 1996), both of which have an inhibitory action on the  $\text{Na}^+$  channel, attenuate  $\text{H}_2\text{O}_2$ -induced myocardial derangements. Those results suggested that inhibition of the  $\text{Na}^+$  channel is effective in attenuating  $\text{H}_2\text{O}_2$ -induced myocardial derangements. Electrophysiological studies have demonstrated that  $\text{H}_2\text{O}_2$  increases the  $\text{Na}^+$  current in ventricular myocytes, but the increase is blocked by tetrodotoxin (Bhatnagar et al 1990; Ward & Giles 1997). Ver Donck & Borgers (1991) have shown that inhibition of the  $\text{Na}^+$  channel with tetrodotoxin attenuates hypercontraction induced by singlet oxygen in cardiomyocytes, supporting our findings of the beneficial action of  $\text{Na}^+$  channel inhibitors on reactive oxygen species. 5-(*N,N*-Dimethyl)-amiloride (15  $\mu\text{M}$ ), like tetrodotoxin, attenuated  $\text{H}_2\text{O}_2$ -induced mechanical and metabolic derangements in the

heart, although the low concentration of 5-(*N,N*-dimethyl)-amiloride (5  $\mu\text{M}$ ) did not. 5-(*N,N*-Dimethyl)-amiloride (15  $\mu\text{M}$ ) is capable of inhibiting the  $\text{Na}^+/\text{H}^+$  exchanger in the heart (half-maximal effective concentration = 7  $\mu\text{M}$ ) without significant action on the  $\text{Na}^+$  channel,  $\text{Ca}^{2+}$  channel,  $\text{Na}^+/\text{Ca}^{2+}$  exchanger or  $\text{Na}^+,\text{K}^+$  ATPase (Kleyman & Cragoe 1988; Dennis et al 1990). Hoque & Karmazyn (1997) have shown that HOE-642 (4-isopropyl-3-methylsulphonylbenzoyl-guanidine methanesulphonate), another specific inhibitor of the  $\text{Na}^+/\text{H}^+$  exchanger, attenuated  $\text{H}_2\text{O}_2$ -induced derangements in the isolated perfused heart. These findings indicated that inhibition of the  $\text{Na}^+/\text{H}^+$  exchanger was effective in attenuating  $\text{H}_2\text{O}_2$ -induced myocardial derangements. We did not measure the intracellular concentrations of  $\text{H}^+$  and  $\text{Na}^+$  in the  $\text{H}_2\text{O}_2$ -treated heart in the present study. It is possible that intracellular concentrations of both  $\text{H}^+$  and  $\text{Na}^+$  increase after  $\text{H}_2\text{O}_2$  administration, because in the cultured cardiac myocytes  $\text{H}_2\text{O}_2$  induces a decrease in intracellular pH (Wu et al 1996) and stimulates the  $\text{Na}^+/\text{H}^+$  exchanger via activation of mitogen-activated protein kinase to increase the intracellular  $\text{Na}^+$  concentration (Sabri et al 1998).

The results of this study demonstrated that either tetrodotoxin (3  $\mu\text{M}$ ) alone or 5-(*N,N*-dimethyl)-amiloride (15  $\mu\text{M}$ ) alone attenuated the  $\text{H}_2\text{O}_2$ -induced increase in LVEDP almost completely. A possible explanation for this finding is that there is a threshold concentration for intracellular  $\text{Na}^+$  to stimulate  $\text{Ca}^{2+}$  influx via the  $\text{Na}^+/\text{Ca}^{2+}$  exchanger as demonstrated by Mullins et al (1983), and that either tetrodotoxin alone or 5-(*N,N*-dimethyl)-amiloride alone can attenuate the  $\text{H}_2\text{O}_2$ -induced increase in intracellular  $\text{Na}^+$  concentration to the threshold level. Interestingly, Eng et al (1998) demonstrated that either tetrodotoxin alone or HOE-642 alone attenuated the ischaemia-reperfusion damage in rat hearts and that there was no additive effect when these drugs were given simultaneously. The concentrations of tetrodotoxin (3  $\mu\text{M}$ ) and 5-(*N,N*-dimethyl)-amiloride (15  $\mu\text{M}$ ) needed to protect the  $\text{H}_2\text{O}_2$ -treated heart are high enough to attenuate myocardial derangements induced by ischaemia-reperfusion in the isolated perfused heart (Duff et al 1988; Dennis et al 1990; Meng & Pierce 1990; Maddaford & Pierce 1997). Therefore, it is possible that the beneficial action of inhibitors of the  $\text{Na}^+$  channel and the  $\text{Na}^+/\text{H}^+$  exchanger against the  $\text{H}_2\text{O}_2$ -induced changes contributes to their protective effect on the myocardium against ischaemia-reperfusion damage.

In conclusion, inhibition of  $\text{Na}^+$  channel or  $\text{Na}^+/\text{H}^+$  exchanger is effective in attenuating



H<sub>2</sub>O<sub>2</sub>-induced mechanical dysfunction and metabolic derangements in the isolated perfused rat heart. This action of both inhibitors may contribute to their protective action on the myocardium against ischaemia-reperfusion damage. Nevertheless, we did not examine the effects of tetrodotoxin and 5-(*N,N*-dimethyl)-amiloride on intracellular concentrations of Na<sup>+</sup> and Ca<sup>2+</sup> in the H<sub>2</sub>O<sub>2</sub>-treated heart. Therefore, further studies are needed to determine detailed mechanisms of the protective action of inhibitors of the Na<sup>+</sup> channel and the Na<sup>+</sup>/H<sup>+</sup> exchanger on the H<sub>2</sub>O<sub>2</sub>-induced derangements.

#### Acknowledgements

The authors thank Mr Tadahiko Yokoyama for his technical assistance, and Ms Miwa Kashu and Ms Kaori Inaba for their secretarial assistance. We also wish to thank Mr Simon Bayley for his help in preparing the manuscript. This research was supported by the grant provided by the Hokkaido Heart Association of Japan and NISHINOMIYA Basic Research Fund of Japan.

#### References

- Bergmeyer, H. U. (ed.) (1974) *Methods of Enzymatic Analysis*. Academic Press, New York, pp 1777–1781, 2101–2110, 2127–2131
- Bhatnagar, A., Srivastava, S. K., Szabo, G. (1990) Oxidative stress alters specific membrane currents in isolated cardiac myocytes. *Circ. Res.* 67: 535–549
- Brown, J. M., Terada, L. S., Grosso, M. A., Whitmann, G. J., Velasco, S. E., Patt, A., Harken, A. H., Repine, J. E. (1988) Xanthine oxidase produces hydrogen peroxide which contributes to reperfusion injury of ischemic, isolated, perfused rat hearts. *J. Clin. Invest.* 81: 1297–1301
- Catterall, W. A., Coppersmith, J. (1981) Pharmacological properties of sodium channels in cultured rat heart cells. *Mol. Pharmacol.* 20: 533–542
- Ceconi, C., Cargnon, A., Pasini, E., Condorelli, E., Curello, S., Ferrari, R. (1991) Evaluation of phospholipid peroxidation as malondialdehyde during myocardial ischemia and reperfusion injury. *Am. J. Physiol.* 260: H1057–H1061
- Dennis, S. C., Coetzee, W. A., Cragoe, E. J., Opie, L. H. (1990) Effects of proton buffering and of amiloride derivatives on reperfusion arrhythmias in isolated rat hearts: possible evidence for an arrhythmogenic role of Na<sup>+</sup>-H<sup>+</sup> exchange. *Circ. Res.* 66: 1156–1159
- Duff, H. J., Sheldon, R. S., Cannon, N. J. (1988) Tetrodotoxin: sodium channel specific anti-arrhythmic activity. *Cardiovasc. Res.* 22: 800–807
- Eng, S., Maddaford, T. G., Kardami, E., Pierce, G. N. (1998) Protection against myocardial ischemic/reperfusion injury by inhibitors of two separate pathways of Na<sup>+</sup> entry. *J. Mol. Cell Cardiol.* 30: 829–835
- Fisher, A. B. (1988) Intracellular production of oxygen-derived free radicals. In: Halliwell, B. (ed.) *Oxygen Radicals and Tissue Injury*. The Upjohn Company, Bethesda, pp 34–39
- Goldhaber, J. I. (1996) Free radicals enhance Na<sup>+</sup>/Ca<sup>2+</sup> exchange in ventricular myocytes. *Am. J. Physiol.* 271: H823–H833
- Hara, A., Abiko, Y. (1996) Protective effects of dilazep and its novel derivative, K-7259, on mechanical and metabolic derangements induced by hydrogen peroxide in the isolated perfused rat heart. *J. Pharmacol. Exp. Ther.* 277: 565–571
- Hara, A., Matsumura, H., Abiko, Y. (1993) Lidocaine attenuates both mechanical and metabolic changes induced by hydrogen peroxide in the rat heart. *Am. J. Physiol.* 265: H1478–H1485
- Hess, M. L., Manson, N. H. (1984) Molecular oxygen: friend and foe: the role of the oxygen free radical system in the calcium paradox, the oxygen paradox and ischemia/reperfusion injury. *J. Mol. Cell Cardiol.* 16: 969–985
- Hoque, A. N. E., Karmazyn, M. (1997) Effect of sodium-hydrogen exchange inhibition on functional and metabolic impairment produced by oxidative stress in the isolated rat heart. *Can. J. Physiol. Pharmacol.* 75: 326–334
- Kim, M.-S., Akera, T. (1987) O<sub>2</sub> free radicals: cause of ischemia-reperfusion injury to cardiac Na<sup>+</sup>-K<sup>+</sup>-ATPase. *Am. J. Physiol.* 252: H252–H257
- Kleyman, T. R., Cragoe, E. J. (1988) Amiloride and its analogs as tools in the study of ion transport. *J. Membrane Biol.* 105: 1–21
- Kokita, N., Hara, A. (1996) Propofol attenuates hydrogen peroxide-induced mechanical and metabolic derangements in the isolated rat heart. *Anesthesiology* 84: 117–127
- Koller, P. T., Bergmann, S. R. (1989) Reduction of lipid peroxidation in reperfused isolated rabbit hearts by diltiazem. *Circ. Res.* 65: 838–846
- Koster, J. F., Slee, R. G., Essed, C. E., Stam, H. (1985) Studies on cumen hydroperoxide-induced lipid peroxidation in the isolated perfused rat heart. *J. Mol. Cell Cardiol.* 17: 701–708
- Loesser, K. E., Kukreja, R. C., Kazziha, S. Y., Jesse, R. L., Hess, M. L. (1991) Oxidative damage to the myocardium: a fundamental mechanism of myocardial injury. *Cardio-science* 2: 199–216
- Lucchini, B. R. (1990) Myocardial ischemia, reperfusion and free radical injury. *Am. J. Cardiol.* 65: 141–231
- Maddaford, T. G., Pierce, G. N. (1997) Myocardial dysfunction is associated with activation of Na<sup>+</sup>/H<sup>+</sup> exchange immediately during reperfusion. *Am. J. Physiol.* 273: H2232–H2239
- Meng, H.-P., Pierce, G. N. (1990) Protective effects of 5-(*N,N*-dimethyl)amiloride on ischemia-reperfusion injury in hearts. *Am. J. Physiol.* 258: H1615–H1619
- Mullins, L. J., Tiffert, T., Vassort, G., Whittembury, J. (1983) Effects of internal sodium and hydrogen ions and of external calcium ions and membrane potential on calcium entry in squid axons. *J. Physiol.* 338: 295–319
- Nakamura, K., Ichihara, K., Abiko, Y. (1989) Effect of lidocaine on accumulation of non-esterified fatty acids in the ischemic perfused rat heart. *Eur. J. Pharmacol.* 169: 259–267
- Nakaya, H., Tohse, N., Kanno, M. (1987) Electrophysiological derangements induced by lipid peroxidation in cardiac tissue. *Am. J. Physiol.* 253: H1089–H1097
- Nasa, Y., Hoque, A. N. E., Ichihara, K., Hashizume, H., Abiko, Y. (1997) Protective effect of amiloride against reperfusion damage as evidenced by inhibition of accumulation of free fatty acids in working rat hearts. *Jpn. Circ. J.* 61: 1021–1029
- Okamura, T., Sunamori, M., Suzuki, A. (1982) Protective effect of lidocaine in reperfused ischemic myocardium: evaluation by hemodynamic and biochemical study. *Jpn. Circ. J.* 46: 657–662
- Pike, M. M., Luo, C. S., Clark, M. D., Kirk, K. A., Kitakaze, M., Madden, M. C., Cragoe, E. J., Pohost, G. M. (1993) NMR measurements of Na<sup>+</sup> and cellular energy in ischemic rat heart: role of Na<sup>+</sup>-H<sup>+</sup> exchange. *Am. J. Physiol.* 265: H2017–2026

- Requena, J., Whittembury, J., Tiffert, T., Eisner, D. A., Mullins, L. J. (1985) The influence of chemical agents on the level of ionized  $[Ca^{2+}]$  in squid axons. *J. Gen. Physiol.* 85: 789–804
- Rogart, R. B. (1987) High-STX-affinity vs. low-STX-affinity  $Na^+$  channel subtypes in nerve, heart, and skeletal muscle. *Ann. NY Acad. Sci.* 479: 402–430
- Rowe, G. T., Manson, N. H., Caplan, M., Hess, M. L. (1983) Hydrogen peroxide and hydroxyl radical mediation of activated leukocyte depression of cardiac sarcoplasmic reticulum. Participation of the cyclooxygenase pathway. *Circ. Res.* 53: 584–591
- Sabri, A., Byron, K. L., Samarel, A. M., Bell, J., Lucchesi, P. A. (1998) Hydrogen peroxide activates mitogen-activated protein kinases and  $Na^+-H^+$  exchange in neonatal rat cardiac myocytes. *Circ. Res.* 82: 1053–1062
- Takeo, S., Tanonaka, K., Shimizu, K., Hirai, K., Miyake, K., Minematsu, R. (1988) Beneficial effects of lidocaine and disopyramide on oxygen-deficiency-induced contractile failure and metabolic disturbance in isolated rabbit hearts. *J. Pharmacol. Exp. Ther.* 248: 306–314
- Tytgat, J., Vereecke, J., Carmeliet, E. (1990) A combined study of sodium current and T-type calcium current in isolated cardiac cells. *Pflügers Arch.* 417: 142–148
- Van Emous, J. G., Nederhoff, M. G. J., Ruigrok, T. J. C., Van Echteld, C. J. A. (1997) The role of the  $Na^+$  channel in the accumulation of intracellular  $Na^+$  during myocardial ischemia: consequences for post-ischemic recovery. *J. Mol. Cell Cardiol.* 29: 85–96
- Ver Donck, L., Borgers, M. (1991) Myocardial protection by R56865: a new principle based on prevention of ion channel pathology. *Am. J. Physiol.* 261: H1828–H1835
- Ward, C. A., Giles, W. R. (1997) Ionic mechanism of the effects of hydrogen peroxide in rat ventricular myocytes. *J. Physiol.* 500: 631–642
- Wu, M.-L., Tsai, K.-L., Wang, S.-M., Wu, J.-C., Wang, B.-S., Lee, Y.-T. (1996) Mechanism of hydrogen peroxide and hydroxyl free radical-induced intracellular acidification in cultured rat cardiac myoblasts. *Circ. Res.* 78: 564–572
- Yanagida, S., Luo, C. S., Doyle, M., Pohost, G. M., Pike, M. M. (1995) Nuclear magnetic resonance studies of cationic and energetic alterations with oxidant stress in the perfused heart: modulation with pyruvate and lactate. *Circ. Res.* 77: 773–783